Christiaansen Allison F, Dixit Upasna Gaur, Coler Rhea N, Marie Beckmann Anna, Reed Steven G, Winokur Patricia L, Zimmerman M Bridget, Varga Steven M, Wilson Mary E
Department of Microbiology, University of Iowa, Iowa City, IA 52242, USA.
Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
Vaccine. 2017 Jul 24;35(33):4255-4261. doi: 10.1016/j.vaccine.2017.06.013. Epub 2017 Jun 27.
Determining the efficacy of human vaccines that induce antigen-specific protective CD4 T cell responses against pathogens can be particularly challenging to evaluate. Surface expression of CD11a and CD49d has been shown to identify antigen-specific CD4 T cells against viral pathogens in mice. We hypothesized that CD11a and CD49d would also serve as markers of human antigen-specific T cells responding to vaccination.
A phase I vaccine trial enabled us to evaluate a novel gating strategy based on surface expression of CD11a and CD49d as a means of detecting antigen-specific, cytokine producing CD4 and CD8 T cells induced after vaccination of naïve individuals against leishmaniasis. Three study groups received LEISH-F3 recombinant protein combined with either squalene oil-in-water emulsion (SE) alone, SE with the synthetic TLR-4 ligand glucopyranosyl lipid adjuvant (GLA-SE), or SE with Salmonella minnesota-derived monophosphoryl lipid A (MPL-SE). Individuals were given 3 vaccine doses, on days 0, 28 and 168.
Starting after the first vaccine dose, the frequency of both CD11aCD49d CD4 and CD11aCD49d CD8 T cells significantly increased over time throughout the 24-week trial. To confirm the role of CD11aCD49d expression in the identification of the antigen-specific T cells, cytokine production was measured following LEISH-F3 stimulation. All of the IFN-γ, TNF-α, and IL-2 producing cells were found within the CD11aCD49d population.
Our results suggest that the change in the frequency of CD11aCD49d T cells can be used to track antigen-specific CD4 and CD8 T cell responses following T cell-targeted vaccination.
确定能够诱导针对病原体的抗原特异性保护性CD4 T细胞应答的人类疫苗的效力,可能极具挑战性。已证明CD11a和CD49d的表面表达可识别小鼠中针对病毒病原体的抗原特异性CD4 T细胞。我们推测CD11a和CD49d也可作为人类针对疫苗接种产生应答的抗原特异性T细胞的标志物。
一项I期疫苗试验使我们能够评估基于CD11a和CD49d表面表达的新型门控策略,以此作为检测初免个体接种利什曼病疫苗后诱导产生的抗原特异性、产生细胞因子的CD4和CD8 T细胞的一种手段。三个研究组分别接受单独的角鲨烯水包油乳剂(SE)、与合成TLR-4配体吡喃葡萄糖基脂质佐剂(GLA-SE)联合的SE或与明尼苏达沙门氏菌来源的单磷酰脂质A(MPL-SE)联合的SE,同时给予LEISH-F3重组蛋白。个体在第0、28和168天接受3剂疫苗。
在首次接种疫苗后,在整个24周的试验过程中,CD11aCD49d CD4和CD11aCD49d CD8 T细胞的频率均随时间显著增加。为证实CD11aCD49d表达在鉴定抗原特异性T细胞中的作用,在LEISH-F3刺激后测量细胞因子产生情况。所有产生IFN-γ、TNF-α和IL-2的细胞均存在于CD11aCD49d群体中。
我们的结果表明,CD11aCD49d T细胞频率的变化可用于追踪以T细胞为靶点的疫苗接种后抗原特异性CD4和CD8 T细胞的应答情况。